A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat

Umibecestat, an orally active β‐secretase inhibitor, reduces the production of amyloid beta‐peptide that accumulates in the brain of patients with Alzheimer’s disease. The echocardiogram effects of umibecestat, on QTcF (Fridericia‐corrected QT), on PR and QRS and heart rate (HR), were estimated by c...

Descripción completa

Detalles Bibliográficos
Autores principales: Vormfelde, Stefan Viktor, Pezous, Nicole, Lefèvre, Gilbert, Kolly, Carine, Neumann, Ulf, Jordaan, Pierre, Ufer, Mike, Legangneux, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719381/
https://www.ncbi.nlm.nih.gov/pubmed/32583957
http://dx.doi.org/10.1111/cts.12832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719381/
https://www.ncbi.nlm.nih.gov/pubmed/32583957
http://dx.doi.org/10.1111/cts.12832

Ejemplares similares